Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections

Clinical Infectious Diseases

Volumn 40, Issue SUPPL., 2005, Pages

  Burgess, David S ^a,b,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFPIROME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ENOXACIN; IMIPENEM; LOMEFLOXACIN; MEROPENEM; NETILMICIN; OFLOXACIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; HUMAN; MEMBRANE PERMEABILITY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OPTIMAL DRUG DOSE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 13944278028     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/426189     Document Type: Article

References (42)

1. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998; 27(Suppl 1):S93-9.
2. Nikaido H. Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin Infect Dis 1998; 27(Suppl 1):S32-41.
3. Aeschlimann JR. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other Gram-negative bacteria. Pharmacotherapy 2003; 23:916-24.
4. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158:831-47.
5. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22:89-96.
6. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 1997; 41:2053-6.
7. Tarn VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50:425-8.
8. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998; 27:10-22.
9. Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 2000; 22:66-75.
10. Tam VH, Louie A, Lomaestro BM, Drusano GL. Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa. Pharmacotherapy 2003; 23:291-5.
11. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31:1054-60.
12. Lacy MK, Nicolau DP, Nightingale CH, Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998; 27:23-7.
13. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159:281-92.
14. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77:657-62.
15. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-9.
16. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984; 149:443-8.
17. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43:623-9.
18. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39:650-5.
19. Murry KR, McKinnon PS, Mitrzyk B, Rybak MJ. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 1999; 19:1252-60.
20. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19:261-8.
21. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37:483-90.
22. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42:521-7.
23. MacGowan AP, Wootton M, Holt HA. The antibacterial efficacy of levofloxacin and ciprofloxacin against Pseudomonas aeruginosa assessed by combining antibiotic exposure and bacterial susceptibility. J Antimicrob Chemother 1999; 43:345-9.
24. Bayer Pharmaceuticals. Cipro (ciprofloxacin) I.V. [package insert]. West Haven, CT: Bayer Pharmaceuticals, 2002.
25. Ortho-McNeil Pharmaceutical. Levaquin tablets/injection [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, 2002.
26. Echols RM. The approval process for intravenous ciprofloxacin. Infect Med 1992; 9:23-31.
27. Echols RM. The selection of appropriate dosages for intravenous ciprofloxacin. J Antimicrob Chemother 1993; 31:783-7.
28. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119:1114-22.
29. Rodvold KA, Danziger LH, Gotfried MH. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob Agents Chemother 2003; 47:2450-7.
30. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003; 112:275-85.
31. Rebuck JA, Fish DN, Abraham E. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit. Pharmacotherapy 2002; 22:1216-25.
32. Goldberg J, Owens RC Jr. Optimizing antimicrobial dosing in the critically ill patient. Curr Opin Crit Care 2002; 8:435-40.
33. Burgess DS, Hastings RW. Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill. Diagn Microbiol Infect Dis 2000; 38:37-41.
34. Burgess DS, Nathisuwan S. Cefepime, pipericillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2002; 44:35-41.
35. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540-6.
36. Gould IM, Milne K. In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin. J Antimicrob Chemother 1997; 39:53-61.
37. Burgess DS, Hall RG, Hardin TC. In vitro evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2003; 46:131-7.
38. Lister PD, Woher DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin Infect Dis 2005;40(Suppl 2):S105-14 (in this issue).
39. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-85.
40. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-74.
41. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-15.
42. Madaras-Kelly KJ, Larsson AJ, Rotschafer JC. A pharmacodynamic evaluation of ciprofloxacin and ofloxacin against two strains of Pseudomonas aeruginosa. J Antimicrob Chemother 1996; 37:703-10.